Protalex has enrolled the first of three patients in the fourth cohort of its PRTX-100-202 Study, a Phase I/II trial of PRTX-100 for the treatment of adults with persistent/chronic Immune Thrombocytopenia (ITP).

Based in the US, the patient has already received 12mg/kg, which is double the dose used in the prior cohort of PRTX-100 6mg/kg.

The opening of the fourth cohort in the US and UK was carried out after a planned, interim analysis of safety and efficacy data received from cohort three.

“Opening additional clinical sites in the UK will facilitate increased enrolment, and support trial completion within the next several months.”

The open-label, dose-escalation PRTX-100-202 study seeks to enrol patients in up to six cohorts.

During the study, patients will receive four weekly intravenous doses of PRTX-100 and are kept under observation for up to 48 weeks thereafter.

Its primary objective is a platelet response to PRTX-100, while secondary objectives include safety, immunogenicity, and pharmacokinetics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial is currently enrolling patients at various clinical sites in the US and the UK.

Protalex ITP Programs vice-president Richard Francovitch said: “Opening additional clinical sites in the UK will facilitate increased enrolment, and support trial completion within the next several months.

“As noted previously, we are encouraged by the data collected in prior cohorts treated at lower doses. The ability to compare dosing outcomes at multiple levels will inform our next step for the development of PRTX-100.”

PRTX-100 has previously received orphan drug designation in the US and Europe for the treatment of ITP, an autoimmune condition characterised by bruising and increased bleeding due to immune-mediated accelerated destruction of platelets and impaired production of platelets.